Kornimate/medical-research-clean huggingface dataset:
meloxicam versus ibuprofen for pain control after third molar exodontia in adult patients

Conditions: Dental Pain; Sensation Disorders

Summary: third molar extraction is a common dental procedure, offently related with pain and swelling. the purpose of this study is to evaluate if meloxicam has a better effect relieving pain after the extraction than ibuprofen, one of the most common pain relieving drugs administered after this procedure.

summary: third molar extractions are one of the most common procedures in dental practice. however, pain and swelling as postoperative sequelae are inevitable. depending on the level of pain, which can range from moderate to severe, this symptomatology can be accompanied with pharmacological treatment, thus generating a less traumatic recovery for the patient. it is currently known that non-steroidal anti-inflammatory drugs (nsaids) have proven to be effective for the treatment of mild and moderate postoperative pain. due to the wide variety of nsaids, it is important to know how to choose the most effective option when indicating one therapeutic option over another. objective: to evaluate the postoperative analgesic effectiveness of meloxicam (7.5 mg) compared to ibuprofen (400 mg) in patients undergoing third molar(s) extraction. design: randomized controlled clinical trial, double-masked, designed according to consort guideline requirements.

Eligibility criteria:
inclusion criteria: maxillary or mandibular third molar with semi or fully erupted crown. exclusion criteria: patients with systemic pathologies. presence of third molar localized infection. completely included third molar crown. periodontal compromise. pregnant or breastfeeding women. patients with hypersensitivity to nsaids. patients with a history of drug abuse. patients who had taken any drug in the previous 24 hours. intervention (exodontia) time longer than 45 minutes.

Keywords: tooth extraction molar, third meloxicam ibuprofen
a study to compare the conversion to prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure

Conditions: Graft Rejection; Kidney Transplantation

Summary: a study to compare the conversion to prograf® (tacrolimus) to the continuation of cyclosporine in patients at risk for chronic renal allograft failure

a two arm study (1 active, 1 active control) to compare the incidence, progression and severity of chronic renal allograft failure in at-risk patients who are converted from cyclosporine-based to tacrolimus-based immunosuppression to patients who remain on cyclosporine-based therapy

Eligibility criteria:
inclusion criteria: * patient has been on cyclosporine-based immunosuppression regimen since the transplant * patient has at least one pre-defined risk factor for chronic allograft failure exclusion criteria: * patient is dialysis dependent * patient is recipient of a solid organ transplant other than the kidney

Keywords: treatment efficacy transplantation rejection kidney transplantation cyclosporine tacrolimus
autoset for her clinical trial protocol

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to assess the efficacy and user preference of the newport autoset for her in female obstructive sleep apnea (osa) patients. efficacy will be evaluated by comparing the apnea and hypopnea index (ahi) and oxygen desaturation index (odi) of the newport autoset for her algorithm to a standard algorithm. user preference will be evaluated by subjective feedback relating to comfort, ease of falling asleep, sleep disturbance and feeling of being refreshed.


Eligibility criteria:
inclusion criteria: * pre-menopausal females aged ≥ 18 years * current positive airway pressure (pap)(cpap or apap) therapy user with 'current' defined as on pap therapy for at least 1 month prior to study entry * diagnostic psg available * diagnosis of mild-moderate osa (ahi ≤ 30) * participants willing and able to give written informed consent exclusion criteria: * participants currently using bi-level pap * participants currently using supplemental oxygen * participants who are pregnant * subjects who have a pre existing lung disease/ condition that would predispose them to pneumothorax (for example: copd, lung cancer; fibrosis of the lungs; recent (\< 2years) case of pneumonia or lung infection; lung injury) * participants who the researcher believes are unsuitable for inclusion because either: * they do not comprehend english * they are unable to provide written informed consent * they are physically unable to comply with the protocol

Keywords: obstructive sleep apnea efficacy subjective feedback preference
tranexamic acid in trauma surgery tranexamic acid in trauma surgery tranexamic acid in trauma surgery

Conditions: Tranexamic Acid; Trauma; Lower Extremity Fracture

Summary: this study was done to evaluate the efficacy of tranexamic acid (txa) in reducing blood transfusion requirement in patients of lower limb trauma undergoing surgery.

this was a single centre, parallel group, prospective randomized control study. 116 patients of lower limb trauma presented between april 2017 to august 2018 at civil hospital rajpura. 16 patients were excluded due to old fracture, percutaneous wire fixation or non-consenting patient. the remaining 100 patients were randomized into two groups. 50 patients were given 1 gram of txa before surgery and 50 patients were not given txa. fall in hb, requirement of blood transfusion, number of days admitted in the hospital after surgery and evidence of deep vein thrombosis were monitored.

Eligibility criteria:
inclusion criteria: * patients suffering from lower limb trauma exclusion criteria: * presence of old implant or infection at the fracture site, * any blood coagulation disorder * patients undergoing percutaneous wire placement procedures for fracture fixation * polytrauma * non-consenting patients * psychiatric patient

Keywords: tranexamic acid deep vein thrombosis blood transfusion
opu-lux: virtual reality for pain and anxiety management during oocyte pick-up

Conditions: Pain, Postoperative; IVF

Summary: in vitro fertilization (ivf) cycles are increasingly performed worldwide. transvaginal oocyte pick-up (opu) is a painful part of ivf. opu in polyfollicular ivf is usually performed under sedation and pain relief. in natural cycle ivf or ivf with minimal stimulation opu is possible without anesthesia. mostly of the women reported experiencing mild to moderate pain when undergoing opu without anesthesia. nevertheless, there is a need for alternative pain treatment options during opu to reduce the burden of ivf for patients. virtual reality (vr) may have a role in acutely painful procedures as a non-pharmacological alternative. vr refers to the interactions between an individual and a computer-generated environment stimulating multiple sensory modalities. the immersive, entertaining effects of vr could be useful for redirecting the patient's attention away from painful treatment experiences and reducing anxiety, discomfort, or unpleasantness. use of vr interventions has been studies in a wider range of medical treatment.


Eligibility criteria:
inclusion criteria: * age between 18 and 43 years * ivf with follicular aspiration of one to tree follicles * written informed consent signed by the participant must be obtained prior to opu exclusion criteria: * opu with more than tree follicular aspiration * individuals' anatomy complicating the intervention (e. g. endometriosis stage iii/iv) * application of analgesics within eight hours before opu * hearing impairments * migraines * seizure disorder * vestibular abnormalities * history of motion sickness
rituxan and beam with autologous peripheral blood progenitor transplant for indolent lymphoma

Conditions: Lymphoma

Summary: to determine the response rate, complete and partial, of patients with indolent lymphoma receiving rituxan and beam with autologous stem cell transplant.

objectives: i. to determine the response rate, complete and partial, of patients with indolent lymphoma receiving rituxan and beam with autologous stem cell transplant. ii. to determine if the addition of rituxan changes the toxicity profile attributed to high-dose beam chemotherapy. this protocol is a phase i/ii trial combining the rituxan as a pre and post-transplant agent to aid in the chemotherapy sensitization and the treatment of minimal residual disease post-transplant.

Eligibility criteria:
inclusion criteria: * any low-grade b-cell, cd20 positive, non-hodgkin's lymphoma that is felt to otherwise be a transplant candidate (relapsed, induction failure, first pr or cr). o small lymphocytic, marginal zone, mantle cell, and follicular histologies. * at least 19 years of age * signed written informed consent * expected survival of at least 6 months * who performance status greater or equal to 2 * male or female subjects of reproductive potential who are able to follow accepted birth control measures. exclusion criteria: * no history of t-cell lymphoma * not pregnant or lactating women * no serious disease or condition that, in the opinion of the investigator, would compromise the subject's ability to participate in the study
depiction of prostate cancer treatment alternatives in greece

Conditions: Locally Advanced or Metastatic Prostate Cancer.

Summary: a retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed in the greek clinical practice. * target group: patients with locally advanced or metastatic prostate cancer. * the first 10 consecutive patients records that meet the entry criteria.


Eligibility criteria:
inclusion criteria: * patients diagnosed with locally advanced or metastatic prostate cancer after 2002. * patients that received hormonal therapy. exclusion criteria: * males that are aged less than 18 years

Keywords: prostate cancer, treatment alternatives, metastasis
accelerate: doxorubicin and cyclophosphamide followed by paclitaxel with pegfilgrastim and darbepoetin alfa support for the treatment of women with breast cancer

Conditions: Breast Cancer

Summary: this is a study of dose dense doxorubicin/cyclophosphamide (ac) followed by paclitaxel (taxol; t) with pegfilgrastim (neulasta) and darbepoetin alfa support in the adjuvant breast cancer setting.


Eligibility criteria:
inclusion criteria: * breast cancer diagnosis node-positive or high risk node negative * estrogen receptor (er) negative or er positive (stage iia, iib or iiia) disease. exclusion criteria: * metastatic breast cancer * clinically significant cardiac disease

Keywords: breast cancer doses dense chemotherapy growth factor support adjuvant breast cancer
a study of ibi362 evaluating weight loss in obese and overweight chinese subjects

Conditions: Overweight/ Obesity

Summary: this is a study of ibi362 in participants with overweight and obesity. the main purpose is to learn more about how ibi362 affects body weight. the study period including 4-8 weeks dose titration and 40-44 weeks maintain treatment and 12 weeks follow up.


Eligibility criteria:
inclusion criteria: 1. body mass index (bmi) ≥28 kilograms per square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea 2. history of at least one unsuccessful dietary effort to lose body weight exclusion criteria: 1. diabetes mellitus 2. weight change \> 5.0% after diet and exercise control for at least 12 weeks before screening 3. have used or are currently using weight loss drugs within 3 months before screening 4. history of pancreatitis 5. family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia syndrome type 2 (men-2) 6. history of moderate to severe depression，or have a history of serious mental illness 7. any lifetime history of a suicide attempt
parent-based intervention following a weight loss surgery

Conditions: Obesity; Obesity, Childhood

Summary: prevention and early intervention are the most effective methods for influencing eating habits. this study helps fulfill the department of psychiatry's missions of clinical innovation and advancing science. findings will inform future clinical practice, improve the care provided to patients in their important role as parents, and foster interdisciplinary collaborations.

morbid obesity is both highly heritable and affected by environmental factors. the child of a parent undergoing a weight-loss surgery (pwls) is at especially high risk of obesity. the most effective approach to reducing the risk of childhood obesity is a parent-based program. however, adherence remains a challenge, largely due to lack of tailored interventions. typical interventions are not individualized to target the unique characteristics of the family nor timed to be delivered when the family is geared for change. parent-based prevention following a bariatric surgery (pbp-b) is a novel targeted intervention that focuses on parental behaviors important for developing healthy eating and lifestyle behaviors in young children. pbp-b personalizes treatment goals through a focused parent-based approach that includes a family meal. additionally, pbp-b is timed to capitalize on the halo effect period, in which the bmis of the family members of the person undergoing weight loss surgery reduce spontaneously, yet only temporarily. this study will investigate whether pbp-b is feasible, acceptable, and associated with improvement in short-term outcomes that predict long term risks of obesity (e.g., parental feeding practices, child eating behaviors, child physical activity levels, and child sleep hours). ten adults who had weight loss surgery and are the parents of one or more children aged 1-10 will receive pbp-b (with their partners, unless they are single parents). this study will collect important pilot data that will inform the design of future adequately powered studies to test ways to reduce the likelihood of adult obesity in children of a parent who had weight loss surgery.

Eligibility criteria:
inclusion criteria: * the biological parent of a child between 1-10 years of age. * has undergone a weight loss surgery. exclusion criteria: \* current medical condition necessitating more intensive care to manage symptoms.

Keywords: bariatric surgery parent-based prevention
predhict: precision recruitment and engagement of diabetics and hypertensives in clinical studies

Conditions: Cardiovascular Disease

Summary: for the sub-study, this digital navigation tool will both inform/educate, engage, support, and navigate participants and providers through the process of clinical trial participation via personalization (data profiling, adaptive and customized messaging, and tailored digital navigation) in a sample of 100 participants with diabetes and hypertension.

to identify provider- and system-level facilitators (solutions) of clinical trial participation that can be in corporated in the digital navigation tool. we will pay special emphasis on the behavior research volunteerism and altruism and individuals who are at risk for cardio metabolic conditions. to develop solutions that will address patient-, provider and system-level barriers preventing clinical trial participation objective 2: to test the adherence, feasibility, and efficacy of a research volunteerism and altruism component of a health and wellness web app. that provides personalized newsfeeds and curriculum about research and health-related volunteer and altruistic activities versus traditional patient navigation procedures and resources in clinical trial awareness.'awareness/knowledge, attitudes, willingness to participate in clinical trial, self-efficacy, and share knowledge about clinical trial opportunities to social network. to determine which elements of the digital tool and mobil app are associated with increased awareness/knowledge, intent to participate, and contagion

Eligibility criteria:
inclusion criteria: * nyu and/or bellevue patient * diagnosed with htn and pre-diabetes/diabetes * must be english speakers * ownership of a smart phone and are willing to use it to download app built in trialx which will be free for participants * must be ambulatory exclusion criteria: * are unable or unwilling to provide informed consent; * are unable to participate meaningfully in an intervention that involves self-- monitoring using software available in english (e.g., due to uncorrected sight impairment, illiterate, non-english-speaking, dementia); * are institutionalized (e.g., in a nursing home or personal care facility, or those who - are incarcerated and have limited control over self-management) * have a history of heart disease, kidney disease, or retinopathy (to rule-out those with long-standing, undiagnosed t2d)
adalimumab trough concentrations in crohn's disease: a pilot pharmacokinetic study

Conditions: Crohn's Disease

Summary: observational pharmacokinetics study of adalimumab in patients with active refractory crohn's disease who are naïve to tnf antagonist therapy.

adalimumab (adm), a fully human tumor necrosis factor (tnf) antagonist, is effective for treating patients with crohn's disease (cd). a correlation between concentration and effect was observed at distinct time points. the aim was to evaluate the correlation of early longitudinal measurements of adm with different biological markers for disease activity and induction and maintenance of clinical remission. this is a prospective two-center open-label observational study in anti-tnf naïve patients with moderate to severe cd induced with adm 160/80 mg at week 0 and 2 and 40 mg every 2 weeks in monotherapy. all patients should be in need for tnf antagonist therapy and should fulfill standard reimbursement criteria (belgium). serum samples were taken pre and post first injection and at weeks 1, 2, 3, 4, 12, 26 and 52. following parameters were determined: c-reactive protein, albumin, tnf, adm, antibodies to adm, hemoglobin, platelet count and leukocyte count. clinical response and remission was evaluated using the harvey-bradshaw index.

Eligibility criteria:
inclusion criteria: * patients with confirmed diagnosis of crohn's disease, fulfilling the criteria for reimbursement (belgium). * patients with active disease defined as a harvey-bradshaw index \>4 and/or a c-reactive protein concentration \>5 mg/l. * informed consent. exclusion criteria: * patients with ulcerative colitis. * patients treated in placebo controlled trials. * patients unwilling to participate or withdrawing informed consent for this study.

Keywords: adalimumab anti-tnf pharmacokinetics trough level immunogenicity
identification of serum markers for tumor hypoxia in non-small cell lung cancers

Conditions: Lung Cancer

Summary: the purpose of the study is to identify a surrogate serum marker for tumor hypoxia in patients with lung cancers.


Eligibility criteria:
inclusion criteria:- newly diagnosed patients with lung cancer who are undergoing surgical resection of their tumors exclusion criteria:- patients without non-small cell lung cancer
evaluation of tranilast to treat pterygium before excision

Conditions: Pterygium

Summary: recurrent or secondary pterygium often has often a growing fibrovascular tissue more exuberant than the primary. histological findings differ from the primary, since the typical changes in the degenerate connective tissue are absent. the strong immunoreactivity and release of basic fibroblast growth (b-fgf) in cultured fibroblasts of recurrent pterygia suggest that fibroblasts may play an important role in pterygium recurrence. tranilast used is an antiallergic drug that has an inhibitory effect on the release of chemical transmitters, such as histamine and leukotrienes from mast cells as well as a suppressive effect on vascular permeability.this drug also reduces tgf-β1 production and collagen synthesis in various cells. tranilast might reduce pterygium recurrence by suppressing tgf-β1 synthesis in conjunctival fibroblast after pterygium surgery. the investigators want to confirm these findings and also compare the recurrence rate between the two types of surgery. tranilast might be an alternative of mitomycin use, and also less toxic. this study aim to compare the effectiveness of preventing recurrence by using tranilast by topical subconjunctival administration previous to conjunctival autograft transplantation surgery in cases of primary pterygium, and will be perform clinical evaluation and tgf-beta-1 immunohistochemical detection by the anti-tgf-beta 1 antibody as well as fibroblast culture.

this is a prospective, randomised, control trial of 50 participants. twenty five patients in each arm. twenty five patients undergo standard pterygium excision with the fibrin glue (tissucol) conjunctival autograft . twenty five patients undergo pterygium surgery with fibrin glue (tissucol), and subconjunctival injection of 0.1 ml of tranilast 1.0% in the head of pterygium 30 days before surgery. participants will be reviewed, selected, and consented on a pre-assessment day. surgery will be performed 4 at a time on an all day surgery operating list. randomisation of the surgery type will be done at the time of surgery after the pterygium has been excised and the autograft taken. the surgeries will perform by a single surgeon (almeida jr, gc). follow-up will occur at week 1,4, 26, 52. slit lamp examination will indicate pterygium recurrence. corneal recurrence will consider when it 0.5 mm of invaded conjunctival tissue,in the clear cornea from the anatomical limbus. the conjunctival recurrence will consider of any size conjunctive fibrovascular invasion inside the graft. the localization and of immunohistochemical will be perform for tgf-b.

Eligibility criteria:
inclusion criteria: * primary pterygium exclusion criteria: * keratoconjunctivitis sicca * sjögren disease * vernal keratoconjunctivitis * acne rosacea * neurotrophic keratopathy * severe dysfunction of the meibomius glands * use of any immunosuppressive drug, through systemic and topical route * aged under 18 years of age and vulnerable groups * glaucoma and use of ocular hipotensor

Keywords: tranilast fibrin glue primary pterygium conjunctival autograft
a 2-year phase 3 study of cp-690,550 in patients with active rheumatoid arthritis on background methotrexate

Conditions: Arthritis, Rheumatoid

Summary: this study is designed to provide safety and efficacy data to support the development of cp-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.


Eligibility criteria:
inclusion criteria: * adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate exclusion criteria: * pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.

Keywords: double-blind placebo-controlled investigational drug oral therapy safety and efficacy hand and feet x-rays